Search Results - "sodium/glucose cotransporter 2"

Angiotensin receptor blocker-neprilysin inhibitor for heart failure with reduced ejection fraction by Dima Nasrallah, Alaa Abdelhamid, Omar Tluli, Yaman Al-Haneedi, Habib Dakik, Ali H. Eid

Connect to this object online.

Risk of lower limb amputation in diabetic patients using SGLT2 inhibitors DPP4 inhibitors or GLP-1 agonists: a meta-analysis of 2 million patients by Yang Lu, Caiyun Guo

Connect to this object online.

Exploring the clinical utility of DPP-IV and SGLT2 inhibitors in papillary thyroid cancer: a literature review by Angelika Buczyńska, Maria Kościuszko, Adam Jacek Krętowski, Adam Jacek Krętowski, Anna Popławska-Kita

Connect to this object online.

Role and impact of a specialized cardiometabolic clinic in managing high-risk patients with type 2 diabetes and atherosclerotic cardiovascular disease by Taher Modarressi

Connect to this object online.

A Population Pharmacokinetic Study to Compare a Novel Empagliflozin L-Proline Formulation with Its Conventional Formulation in Healthy Subjects by Xu Jiang, Kyung-Sang Yu, Dong Hyuk Nam, Jaeseong Oh

Connect to this object online.

Use of SGLT-2 Inhibitors in Patients With Type 1 Diabetes Mellitus by Lea El Hage MD, Sangeeta R Kashyap MD, Pratibha Rao MD, MPH

Connect to this object online.

Type-2 Diabetes Mellitus: A Review of Current Trends by Priya ​ Patel, Hiren Patel, Hiren Bhagiya, Bhavisha Kacha, Austin Christian

Connect to this object online.

Renoprotective Effect of Thai Patients with Type 2 Diabetes Mellitus Treated with SGLT-2 Inhibitors versus DPP-4 Inhibitors: A Real-World Observational Study by Apichaya Chanawong, Suriyon Uitrakul, Supatcha Incomenoy, Natnicha Poonchuay

Connect to this object online.

Progress of patients hospitalized with acute heart failure treated with empagliflozin by Manuel Raya-Cruz, Javier Gascon Jurado, Gonzalo Olalla de la Torre Peregrıin, Nicolas Montufar, Agusin Rodriguez Sanchez, Francisco Gomez Delgado

Connect to this object online.

Canagliflozin Prevents Lipid Accumulation, Mitochondrial Dysfunction, and Gut Microbiota Dysbiosis in Mice With Diabetic Cardiovascular Disease by Xueliang Wang, Xueliang Wang, Zhe Wang, Di Liu, Hao Jiang, Hao Jiang, Chao Cai, Chao Cai, Guoyun Li, Guoyun Li, Guangli Yu, Guangli Yu

Connect to this object online.

Navigating the therapeutic landscape of SGLT2 inhibitors in diabetes management: exploring efficacy and emerging concerns by Farazul Hoda, Harsha Negi, Digvijaya Saini, Mawrah Arshad, Sidra Zayed, Mukesh Kumar Raut, Mohammad Anwar Habib, Mohd Akhtar, Abul Kalam Najmi

Connect to this object online.

The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence by Gupta M, Rao S, Manek G, Fonarow GC, Ghosh RK

Connect to this object online.

Budd-Chiari syndrome-acute-on-chronic liver failure with simultaneous thrombotic and non-thrombotic acute insults by Vinay Borkar, Mit Shah, Chintan Tailor, Shamshersingh Chauhan, Saiprasad Lad, Vikramaditya Rawat, Yatin Lunagariya, Shivani Chopra, Deepak Sasikumar, Meghraj Ingle

Connect to this object online.

Efficacy and safety of SGLT2 inhibitors in nondiabetic patients with CKD: a review of recent evidence by Junhao Lv, Luying Guo, Rending Wang, Jianghua Chen

Connect to this object online.

The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review by Aurélie Pahud de Mortanges, Dante Salvador Jr, Dante Salvador Jr, Markus Laimer, Taulant Muka, Matthias Wilhelm, Arjola Bano, Arjola Bano

Connect to this object online.

Anti-Inflammation and Anti-Oxidation: The Key to Unlocking the Cardiovascular Potential of SGLT2 Inhibitors and GLP1 Receptor Agonists by Veronika A. Myasoedova, Michele Bozzi, Vincenza Valerio, Donato Moschetta, Ilaria Massaiu, Valentina Rusconi, Daniele Di Napoli, Michele Ciccarelli, Valentina Parisi, Piergiuseppe Agostoni, Stefano Genovese, Paolo Poggio

Connect to this object online.

The Reporting Frequency of Ketoacidosis Events with Dapagliflozin from the European Spontaneous Reporting System: The DAPA-KETO Study by Gabriella di Mauro, Annamaria Mascolo, Mario Gaio, Concetta Rafaniello, Antonella De Angelis, Liberato Berrino, Giuseppe Paolisso, Francesco Rossi, Annalisa Capuano

Connect to this object online.

Tirzepatide for type 2 diabetes by Sarah L Anderson, Joel C Marrs

Connect to this object online.

Structural repurposing of SGLT2 inhibitor empagliflozin for strengthening anti-heart failure activity with lower glycosuria by Yixiang Xu, Chao Zhang, Kai Jiang, Xinchun Yang, Feng Chen, Zhiyang Cheng, Jinlong Zhao, Jiaxing Cheng, Xiaokang Li, Xin Chen, Luoyifan Zhou, Hao Duan, Yunyuan Huang, Yaozu Xiang, Jian Li

Connect to this object online.

Sodium-Glucose Cotransporter Inhibitors: Cellular Mechanisms Involved in the Lipid Metabolism and the Treatment of Chronic Kidney Disease Associated with Metabolic Syndrome by Fernando Cortés-Camacho, Oscar René Zambrano-Vásquez, Elena Aréchaga-Ocampo, Jorge Ismael Castañeda-Sánchez, José Guillermo Gonzaga-Sánchez, José Luis Sánchez-Gloria, Laura Gabriela Sánchez-Lozada, Horacio Osorio-Alonso

Connect to this object online.